Oncology · Colorectal CancerOtherclinicalmid-term

SLC22A4 Variants Influence Fusobacterium nucleatum in Colorectal Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/22/2026, 6:05:06 AM

Assessment confidence: 72% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The identification of SLC22A4 variants as influencers of Fusobacterium nucleatum abundance in colorectal cancer presents a significant opportunity for personalized treatment strategies. This genetic insight may lead to the development of microbiota-targeted therapies, which could enhance treatment efficacy and patient outcomes. Regulatory context from FDA (FDA AP — INQOVI (SUPPL)) supports the near-term read. Assessment grounded in 14 ranked evidence items (10 high-relevance).

Strategic Assessment

Pharma companies developing CRC therapies may need to consider genetic profiling of patients to tailor microbiota-targeted interventions. The strongest clinical anchor is Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (ClinicalTrials.gov), sub-indication match (colorectal cancer). In colorectal cancer, 4 regulatory and 1 competitive items passed relevance filtering for colorectal cancer therapies.

Competitive Pressure

The most relevant competitive pressure comes from CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation (Humanexa Signals) — sub-indication match (colorectal cancer). This finding highlights a potential biomarker for CRC progression and suggests that targeting SLC22A4 could influence treatment strategies involving microbiota modulation.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — INQOVI (SUPPL) (FDA). Regulatory pathway relevance (nda). As genetic profiling becomes integral to treatment strategies, regulatory bodies may require updated guidelines for CRC therapies, impacting approval processes and compliance for new products.

Key Risks

Elevated medium regulatory exposure for colorectal cancer therapies could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Pharma companies may gain a competitive edge by integrating genetic profiling into their CRC treatment protocols, potentially improving market share in the oncology sector. This could also lead to the development of novel therapies that address microbiota dynamics.
Upside for colorectal cancer therapies may improve if Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (ClinicalTrials.gov) delivers favorable follow-through.
Upside for colorectal cancer therapies may improve if Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells. (PubMed) delivers favorable follow-through.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Pharma companies developing CRC therapies may need to consider genetic profiling of patients to tailor microbiota-targeted interventions.

What Would Change This Assessment

This becomes more urgent if Monitor ongoing research into SLC22A4-targeted therapies and their impact on microbiota in CRC patients.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Testing the Addition of New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation
Humanexa Signalshigh relevance
Sub-indication match (colorectal cancer)
FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Genetic variants of the transporter SLC22A4 affect the abundance and survival of Fusobacterium nucleatum in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Discovery of a novel and potent KRAS(G12V)-targeting peptide with antiproliferative activity against colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

colorectal cancer therapies
oncology drug developers

Commercial impact

medium

Pharma companies may gain a competitive edge by integrating genetic profiling into their CRC treatment protocols, potentially improving market share in the oncology sector. This could also lead to the development of novel therapies that address microbiota dynamics.

Regulatory impact

medium

As genetic profiling becomes integral to treatment strategies, regulatory bodies may require updated guidelines for CRC therapies, impacting approval processes and compliance for new products.

What to watch

Monitor ongoing research into SLC22A4-targeted therapies and their impact on microbiota in CRC patients.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.